Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl Sells 3,084 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) General Counsel Bryan Wahl sold 3,084 shares of the company's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $154,539.24. Following the completion of the sale, the general counsel now owns 51,712 shares in the company, valued at $2,591,288.32. This trade represents a 5.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Bryan Wahl also recently made the following trade(s):

• On Tuesday, March 18th, Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $46.29, for a total value of $154,654.89.

Tarsus Pharmaceuticals Stock Up 4.8 %

NASDAQ:TARS traded up $2.39 during trading hours on Monday, reaching $52.36. The company had a trading volume of 1,101,887 shares, compared to its average volume of 643,190. Tarsus Pharmaceuticals, Inc. has a twelve month low of $20.08 and a twelve month high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -13.74 and a beta of 1.05. The business's 50-day simple moving average is $48.59 and its two-hundred day simple moving average is $45.64.

Remove Ads

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. On average, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. HC Wainwright restated a "buy" rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Barclays lowered their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Jefferies Financial Group upped their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Guggenheim reissued a "buy" rating and issued a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Finally, Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $63.67.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in TARS. Mutual of America Capital Management LLC bought a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth $4,291,000. Jennison Associates LLC raised its holdings in Tarsus Pharmaceuticals by 47.2% during the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company's stock worth $71,653,000 after buying an additional 698,712 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Tarsus Pharmaceuticals in the third quarter valued at $282,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 10.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 290,009 shares of the company's stock valued at $9,538,000 after buying an additional 28,130 shares during the last quarter. Finally, FMR LLC increased its position in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after acquiring an additional 3,537 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.